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Longitudinal change of prebronchodilator spirometric obstruction
We read with interest the article by ProbstHensch et al about longitudinal changes of prebronchodilator spirometric values. 1 They reported a non-persistent obstruction rate of 20.9% and concluded that prebronchodilator spirometry values only might misclassify chronic obstructive pulmonary disease (COPD). We are surprised by this high nonpersistence rate and we believe that there are some issues that have to be taken into account regarding the obtained lung function values, irrespective of the quality control. 2 First, we noticed that w40% of the nonpersistent subjects were never-smokers and that the age range of subjects included was large: 18e62 years. COPD screening is not efficient in never-smokers and subjects under 40 years of age. In such subjects normal agerelated decline is expected, and non-persistent obstruction could indicate erroneously lowered baseline forced expiratory volume in 1 s (FEV 1 ) or follow-up forced vital capacity (FVC). We wonder whether exclusion of never-smokers would have given a lower rate. Secondly, there is no explanation provided for the high number of neversmokers that develop airflow obstruction during follow-up. In incident stages I and II, 44.7% and 35.3%, respectively, are neversmokers. We acknowledge that both in smokers and never-smokers lung function decreases with age; however, these numbers seem unusually high. Thirdly, no correction for intraindividual measurement errors was applied. An intraindividual error will be present when measuring FEV 1 /FVC over time. When w94% of the non-persistent cases were mildly obstructive, we wonder whether correction for intraindividual measurement errors would have produced lower non-persistent rates. Fourthly, it would seem that the interindividual SD values of both FVC and FEV 1 /FVC (% predicted) are very low; in non-persistent cases even 0.0. In a random sample from the population one would suspect a stronger variability in lung function values.
We calculated prebronchodilator nonpersistence rate in subjects participating in the NELSON study, a lung cancer screening trial; see table 1. 3 We found a non-persistence rate of 7.0% (52/741) which is far less than the 20.9% reported by Probst-Hensch et al. We believe this rate is of more interest because it is based on high-risk subjects all heavily exposed to tobacco smoking and subsequently at risk to develop COPD. The 3-year follow-up time was shorter than the 11 years in the SAPALDIA study, but in theory this should have led to higher non-persistence rates in our cohort.
Finally, if one treats the results as correct, it remains unknown whether postbronchodilator values would have led to lower non-persistence rates because this was not formally investigated in the study, nor supported by previous studies. 
